Display options
Cite
Verma V, Shrimali RK, Ahmad S, et al. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1. Nat Immunol. 2019;20(11):1555doi: 10.1038/s41590-019-0519-6.
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Flaherty, K. T., Wargo, J. A., Boland, G. M., Sullivan, R. J., Getz, G., Hammond, S. A., Tan, M., Qi, J., Wong, P., Merghoub, T., Wolchok, J., Hacohen, N., Janik, J. E., Mkrtichyan, M., Gupta, S., & Khleif, S. N. (2019). Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1. Nature immunology, 20(11), 1555. https://doi.org/10.1038/s41590-019-0519-6
Verma, Vivek, et al. "Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1." Nature immunology vol. 20,11 (2019): 1555. doi: https://doi.org/10.1038/s41590-019-0519-6
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1. Nat Immunol. 2019 Nov;20(11):1555. doi: 10.1038/s41590-019-0519-6. PMID: 31551574.
Copy Download .nbib Format: NLM
Share it on

Nat Immunol. 2019 Nov;20(11):1555. doi: 10.1038/s41590-019-0519-6.

Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1.

Nature immunology

Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, Winjie Dai, Hua Wang, Sumin Lu, Rahul Nandre, Pankaj Gaur, Jose Lopez, Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, Keith T Flaherty, Jennifer A Wargo, Genevieve M Boland, Ryan J Sullivan, Gad Getz, Scott A Hammond, Ming Tan, Jingjing Qi, Phillip Wong, Taha Merghoub, Jedd Wolchok, Nir Hacohen, John E Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N Khleif

Affiliations

  1. Georgia Cancer Center, Augusta University, Augusta, GA, USA.
  2. The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  3. Therapeutic Discovery, MD Anderson Cancer Center, Houston, TX, USA.
  4. Five Prime Therapeutics Inc., South San Francisco, CA, USA.
  5. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  6. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  7. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  8. Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
  9. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  10. MedImmune LLC, Gaithersburg, MD, USA.
  11. Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University, Washington, DC, USA.
  12. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  13. Weill Cornell Medical and Graduate Schools, New York, NY, USA.
  14. Incyte Inc., Wilmington, DE, USA.
  15. A2 Biotherapeutics, Agoura Hills, CA, USA.
  16. Georgia Cancer Center, Augusta University, Augusta, GA, USA. [email protected].
  17. The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. [email protected].

PMID: 31551574 DOI: 10.1038/s41590-019-0519-6

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Publication Types

Grant support